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D
iabeticretinopathyisthemostwell-
known ocular complication of dia-
betes and the leading cause of
blindness among people 20–64 years of
age in the U.S. (1). Up to 4 million Amer-
icans with diabetes, 40 years of age and
older, have retinopathy, and nearly 1 mil-
lion have sight-threatening retinopathy
(2).Inmajorclinicaltrials,tightcontrolof
blood glucose and blood pressure has
been demonstrated to reduce the risk of
retinopathy and associated blindness (3).
A range of ocular diseases is also as-
sociated with diabetes, which may lead to
visionloss.However,someoftheseocular
conditions may not be familiar to noneye
clinicians(4–6).Inthisreview,weaimto
highlight the frequencies, clinical presen-
tations, natural histories, and manage-
ment of these ocular conditions.
Physicians who manage patients with di-
abetes may beneﬁt from knowledge of
these associated conditions and are thus
able to ensure adequate and timely refer-
ral and treatment. Routine eye screening
for retinopathy of individuals with diabe-
tes offers the opportunity to detect these
other ocular diseases early, many of
whicharesightthreatening.Physicianed-
ucation remains an important public
health strategy in the prevention of vision
loss in patients with diabetes.
OCULAR CONDITIONS
DIRECTLY ASSOCATED
WITH DIABETES
1. Cataracts and cataract surgery
Cataract is a major cause of vision impair-
ment in people with diabetes. Numerous
studies have documented an association
betweendiabetesandcataracts.Thisasso-
ciation is supported by an abundance of
data from clinical epidemiological studies
and basic science studies (7–22). Both
cross-sectional and prospective data from
three population-based studies, the Bea-
ver Dam Eye Study, the Blue Mountains
Eye Study, and the Visual Impairment
Project, have documented associations
between diabetes and both prevalent and
incident posterior subcapsular cataract
and, less consistently, with prevalent and
incident cortical cataracts but not nuclear
cataract (8–12,14–19,23,25). The Blue
Mountains Eye Study showed that im-
paired fasting glucose, in the absence of
clinical diabetes, was also a risk factor for
the development of cortical cataract (7).
There is additional evidence that the risk
of cataract increases with increasing dia-
betesdurationandseverityofhyperglyce-
mia (26). Deposition of advanced
glycation end products in the lens has
been postulated as one possible patho-
genic mechanism for diabetic cataract
(27).
Cataract surgery is the standard treat-
ment for patients with cataract and signif-
icant vision impairment. In individuals
withdiabetes,cataractoccursatayounger
age and progresses more rapidly, result-
ing in higher rates of cataract surgery at a
relatively young age (28). In the Wiscon-
sin Epidemiologic Study of Diabetic Reti-
nopathy, the 10-year cumulative
incidence of cataract surgery was 8% in
those with type 1 diabetes and 25% in
those with type 2 diabetes. Predictors of
cataract surgery included older age,
greater severity of diabetic retinopathy,
and baseline proteinuria in type 1 diabe-
tesandolderageanduseofinsulinintype
2 diabetes (25).
While the overall outcomes of cata-
ract surgery are excellent, patients with
diabetes may have poorer vision out-
comes than those without diabetes, and
the worst outcomes may occur in oper-
atedeyeswithactiveproliferativeretinop-
athy (29) and/or preexisting macular
edema. To improve cataract surgical out-
comes in patients with diabetes, adequate
control of diabetic retinopathy with laser
treatment before cataract surgery is nec-
essary (30).
The most devastating postoperative
complication is endophthalmitis, a severe
intraocular infection, with several studies
showing that patients with diabetes have
an increased risk of developing this com-
plication (31–34), resulting in poorer
outcomes (35). Patients with endoph-
thalmitis characteristically present with
pain, redness, discharge, decreased vi-
sion, eyelid edema, proptosis, and con-
junctivalinjection,withanteriorchamber
inﬂammationandvitritis.Managementof
endophthalmitis consists of inpatient ad-
mission for a combination of intravitreal,
subconjunctival, and topical antibiotics
and steroids and possibly ocular surgery.
In patients with diabetes, treatment may
need to be more aggressive, with surgery
performed earlier rather than later (35).
2. Anterior ischemic optic
neuropathy
Anterior ischemic optic neuropathy
(AION) is an acute vascular condition of
the optic nerve. Studies suggest that up to
25% of patients with AION have a history
ofdiabetes(36).Inpatientswithdiabetes,
diabetic microvascular disease affecting
the anterior part of the optic nerve is
thought to cause the ischemia (37, 38).
The optic disc in the contra-lateral
eye of patients with AION is typically
small in diameter with a small or absent
cup,referredtoasa“discatrisk.”Patients
withAIONusuallypresentwithmoderate
loss of vision upon awakening, presum-
ably related to nocturnal systemic hypo-
tension (39). Visual acuity is better than
20/200 in 60% of cases at presentation
(40). Untreated, AION generally remains
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unusual (41). Good recovery of vision
was observed in 43% of patients in the
Ischemic Optic Neuropathy Decompres-
sion Trial (42).
There are no proven treatments for
AION, and the Ischemic Optic Neuropa-
thyDecompressionTrialrevealednoben-
eﬁt of optic nerve decompression surgery
(43). Currently, neuroprotective agents
are being investigated for nonarteritic
AION (NAION) and appear to be beneﬁ-
cial against secondary neuronal degener-
ationinanimalmodelsofischemicretinal
ganglion cell damage and optic nerve
crushinjury(44).Thereisnoprovenpro-
phylaxis for AION, and the evidence for
the efﬁcacy of aspirin therapy is limited
(45).
3. Diabetic papillopathy
Diabetic papillopathy is an uncommon
optic nerve condition characterized by
acute disc edema and mild vision loss
(46). Diabetic papillopathy is a risk factor
for the progression of diabetic retinopa-
thy(47);and,inrareinstances,papillopa-
thy can precede the development of
AION(48).Earlyinvestigatorspostulated
a toxic effect of abnormal glucose metab-
olism on the optic nerve in individuals
with diabetes; subsequent studies have
suggested that diabetic papillopathy may
be a mild and reversible form of AION
(49).
The signiﬁcance of this condition is
twofold. First, this condition may be mis-
diagnosed as papilledema (50). Second,
telangiectasia at the optic disc in diabetic
papillopathy may be mistaken as neovas-
cularization in the opitc disc as part of
proliferative diabetic retinopathy, leading
to unnecessary laser photocoagulation.
Diabetic papillopathy spontaneously im-
proveswithinayear,andvisionprognosis
is usually good. In most patients, vision
recovers to a level 20/30 (51). Tighten-
ing diabetes control and treating coexis-
tent hypertension and renal dysfunction
may help with resolution of this condi-
tion. There is anecdotal evidence that in-
traocular steroid injection may beneﬁt
patients with vision impairment (52).
4. Ocular movement disorders
Extraocular motility disorders may occur
inpatientswithdiabetes,secondarytodi-
abetic neuropathy, involving the third,
fourth, or sixth cranial nerve. Rarely, si-
multaneous palsies of multiple extraocu-
lar nerves can occur (53,54). Diabetes is
the underlying cause in 25–30% of pa-
tients aged 45 years and older who de-
velop acute extraocular muscle palsy
(55). In one study (56), 1% of patients
with diabetes were found to have cranial
nerve palsies, compared with only 0.13%
of control subjects. Of these cases, 41%
had a third nerve palsy. In another popu-
lation-based study, patients with sixth
cranial nerve palsy were six times more
likely to have diabetes (57).
Patients with extraocular palsies
present with binocular diplopia. Pupil
sparing is an important diagnostic feature
in diabetes-related third cranial nerve
palsy, distinguishing it from surgical
causes, such as intracranial aneurysm or
tumor. In diabetic cranial nerve palsies,
recovery of extraocular muscle function
generally occurs within 3 months (58).
Recurrences can be common and may in-
volve the same or other cranial nerves.
The presence of other focal neurological
signs, progressive deterioration, or palsy
in a patient younger than 45 years should
be investigated to exclude a compressive
lesion. In these instances, a neurology or
neuro-ophthalmologyconsultationisrec-
ommended.
OCULAR CONDITIONS FOR
WHICH DIABETES IS A
KNOWN RISK FACTOR
1. Glaucoma
Glaucoma is a progressive optic neuropa-
thy associated with typical optic disc
changes and visual ﬁeld defects. Elevated
intraocular pressure is the major risk fac-
tor for glaucoma, although a proportion
of patients with glaucoma do not have
raised intraocular pressure. Patients with
diabetes are at risk of two major types of
glaucoma:primaryglaucomaandneovas-
cular glaucoma.
a. Primary glaucoma. Several large epi-
demiological studies have reported posi-
tive associations between diabetes with
primary open angle glaucoma (POAG),
the most common form of primary glau-
coma, or elevated intraocular pressure in
the absence of glaucoma optic neuropa-
thy (59–63). Glaucoma occurs more of-
ten in patients with diabetes (5%) than
in the general population (2%) (64). The
risk of glaucoma has been reported to be
1.6–4.7 times higher in individuals with
diabetes than in nondiabetic individuals
(65–68). In the Blue Mountains and Bea-
verDamEyestudies,participantswithdi-
abetes were twice as likely to have
glaucoma as those without. However, not
all population-based studies have identi-
ﬁed such an association (69–73).
There are clear biologically plausible
mechanisms supporting an association
between diabetes and POAG. First, mi-
crovascular damage from diabetes could
impair blood ﬂow to the anterior optic
nerve, resulting in optic nerve damage
(37,38). Diabetes also impairs the auto-
regulation of posterior ciliary circulation,
which may exacerbate glaucomatous op-
tic neuropathy (74). Second, patients
withdiabetesoftenhaveconcomitantcar-
diovascular risk factors (e.g., hyperten-
sion) that may affect vascular perfusion of
theopticnervehead(75).Finally,relative
to those without diabetes, individuals
with diabetes may be more vulnerable to
elevated intraocular pressure (76), with
more severe visual ﬁeld loss at the same
intraocular pressure level (77).
It is important to screen for POAG
among individuals with diabetes, as
POAG can be asymptomatic until the late
stages,whendecreasedvisionand/orcon-
stricted visual ﬁelds are noted. Treatment
involves lowering intraocular pressure
through topical eye drops and laser and
surgical procedures. Primary angle clo-
sure glaucoma (PACG), the other com-
mon primary glaucoma, is characterized
by narrow or closed anterior chamber an-
gles, which impedes drainage of aqueous
humor and leads to raised intraocular
pressure. Patients with PACG appear to
be more likely to have abnormal glucose
tolerance than those with POAG or those
without glaucoma (78). Diabetes may be
associated with PACG via systemic auto-
nomic dysfunction or increased lens
thickness as a result of sorbitol overload
(79,80). Patients with PACG may present
with an acute attack, which is associated
with severe ocular pain, headaches, and
nausea, with substantially elevated in-
traocular pressure. Acute PACG requires
urgent referral and treatment.
b. Neovascular glaucoma. Studies have
shown a consistent association between
diabetes and neovascular glaucoma (81),
with proliferative retinopathy the leading
cause of this type of secondary glaucoma.
Between32and43%ofneovascularglau-
coma cases are caused by proliferative
diabetic retinopathy (82,83). Neovascu-
larization of the iris, an early precursor of
neovascular glaucoma, is commonly seen
in patients with long-standing poorly
controlled diabetes (84). Hypoxia in the
retina and other ocular tissue causes an
increasedexpressionofvascularendothe-
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lates new vessel formation in the iris (85)
or in the anterior chamber angle (86).
Neovascular glaucoma requires aggres-
sive intervention to lower intraocular
pressure with medication, followed by
surgery (87). Regression of neovascular-
ization following pan-retinal laser photo-
coagulation can occur if treated early
(37,38).
2. Ocular ischemic syndrome
Ocularischemicsyndrome(OIS)isanun-
common vascular problem that results
from chronic hypo-perfusion of the eye,
most commonly caused by ipsilateral in-
ternal carotid or ophthalmic artery occlu-
sion (88). Patients with OIS typically
present with vision loss and dull ocular
pain (87). The prevalence of diabetes in
patients with OIS is higher than in the
general population (69), with one study
reporting that more than 50% of patients
with OIS have diabetes (89). Diabetes is a
major risk factor for carotid artery steno-
sis and plaque formation, the underlying
causes of OIS (90).
The 5-year mortality rate among pa-
tients with OIS has been reported to be
40%orhigher(91).Coexistingcardiovas-
cularandcerebrovasculardiseasesarethe
maincausesofdeath.Carotidultrasonog-
raphy is useful to delineate the presence
and severity of carotid artery stenosis. Al-
though carotid endarterectomy lowers
the risk of stroke in patients with symp-
tomatic carotid stenosis (92), it is unclear
whetherthisprocedurealtersvisionprog-
nosis in eyes with OIS (93,94). The coex-
istence of diabetes with OIS may be an
indicator of poorer vision prognosis, due
tothehigherincidenceofsecondaryglau-
coma (94). Pan-retinal laser photocoagu-
lation is indicated in eyes with ocular
neovascularization.
OCULAR CONDITIONS
WHERE DIABETES IS A
POSSIBLE RISK FACTOR
1. Retinal vein occlusion
Retinal vein occlusion (RVO) is a retinal
vascular condition characterized by di-
lated tortuous retinal veins with retinal
hemorrhages, cotton wool spots, and
macular edema. Central RVO occurs at
the optic disc (95), whereas branch RVO
occurs at retinal venular branches, usu-
ally at the site of arterio-venous crossing
(96).CentralRVOmaybesubdividedfur-
ther into nonischemic and ischemic
types,thelatterassociatedwithpoorervi-
sion prognosis (97). Although it has been
thoughtthatdiabetesisamajorriskfac-
tor for RVO, epidemiological studies
have not shown a consistent relation-
ship between diabetes and the presence
of RVO, with some studies reporting a
positive association (98–102) and oth-
ers ﬁnding no association (103–106).
The importance of RVO in patients with
diabetes is that the retinal signs (e.g.,
hemorrhages or cotton wool spots) may
“mimic” diabetic retinopathy. Thus,
when patients with diabetes present
with acute vision loss and asymmetric
signs of “diabetic” retinopathy, RVO
should be considered.
The management of RVO depends
upon the site of occlusion (central or
branch), degree of ischemia, presence of
macular edema, visual acuity level, and
complications. Approximately 30% of
central RVO cases are initially nonisch-
emic, but 10% progress to ischemia
within 6 months (107). The two major
complications of RVO are secondary neo-
vascular glaucoma and macular edema.
Pan-retinal laser photocoagulation has
been shown to prevent neovascular glau-
coma (108). No treatment has proven ef-
fectiveformacularedemainpatientswith
central RVO, although focal laser treat-
ment may be useful in patients with mac-
ular edema and branch RVO (109).
Clinical trials are on-going to assess the
intraocular administration of pharmaceu-
tical agents, such as steroids (110) or an-
tivascular endothelial growth factor
agents (111,112).
The vision prognosis with central
RVO, particularly ischemic central RVO,
is poor, but that of branch RVO is rela-
tively good, with nearly half of patients
maintaining visual acuity better than
20/40 (113). Patients with diabetes who
develop RVO are more likely than their
nondiabetic counterparts to develop reti-
nalneovascularization(114),neovascular
glaucoma, and vitreous hemorrhage
(112). More importantly, recent studies
suggest that, among those with diabetes
43–69 years of age, the presence of RVO
is associated with double the risk of car-
diovascular mortality (115).
Management of concomitant medical
conditions(e.g.,hypertensionanddyslip-
idemia) may be important to prevent a
recurrence of RVO (116). There is no
good evidence that tight glycemic control
can alter the course or improve the prog-
nosis of RVO.
2. Retinal arteriolar emboli
Retinal arteriolar emboli are discrete
plaque-likelesionslodgedinthelumenof
retinal arterioles. The majority of emboli
areasymptomaticandtransient,although
patients infrequently present with epi-
sodes of sudden, painless, monocular
blindness (amaurosis fugax), a transient
ischemic attack, or stroke (117).
Population-based studies show that
asymptomatic retinal emboli occur in
1.3–1.4% of adults 40 years of age and
older (61,118). Studies show that retinal
arteriolar emboli are associated with ca-
rotid artery disease, hypertension, other
cardiovascular risk factors (117), and an
increasedriskofstrokeandstroke-related
(119,120) and all-cause (121) mortality.
However, there are no consistent data on
whether retinal arteriolar emboli occur
more commonly in people with diabetes.
IntheBeaverDamEyeStudy,participants
with type 2 diabetes were found to have a
twofold higher prevalence of retinal em-
boli(60),buttwootherpopulation-based
studies have failed to conﬁrm this associ-
ation (61,105).
Onceanembolushasbeendetected,a
full cardiovascular and cerebrovascular
risk assessment is recommended, includ-
ing carotid artery ultrasound and echo-
cardiography to assess the source of the
emboli. Treatment of concomitant car-
diovascularriskfactorsisvitalandshould
include improved control of hyperglyce-
mia, hypertension, and hyperlipidemia,
cessation of smoking, and carotid endar-
terectomy, if indicated. Low-dose aspirin
can be recommended to prevent retinal
artery occlusion (122).
3. Retinal artery occlusion
Retinal artery occlusion (RAO) is a retinal
vascular condition similar to emboli. The
hallmark of RAO is sudden, unilateral,
painless loss of vision associated with a
visual ﬁeld defect. Patients with central
RAO usually present with a dramatic loss
of vision, an afferent pupillary defect, dif-
fuse retinal whitening, and the resultant
classic “cherry spot” on the macula. The
fundoscopic ﬁndings with branch RAO,
which occur at a branch, usually consist
of a focal wedge-shaped area of retinal
whitening; vision loss also tends to be
much milder. As for emboli, there is no
clear evidence that patients with diabetes
are at higher risk of RAO. However, the
prevalence of diabetes among patients
with RAO has been reported to be as high
as 21%, which is higher than in the gen-
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(123,124).
Patients with RAO should be referred
immediately to an ophthalmologist for
management. In the acute phase (within
24 h), a variety of treatments have been
proposed, such as ocular massage (to dis-
lodge the embolus) and intravenous acet-
azolamide injection (to lower intraocular
pressure) (125). However, there is no ev-
idence from randomized trials regarding
theefﬁcacyofthesetreatments(126).Itis
important for physicians to measure the
erythrocyte sedimentation rate to exclude
giant cell arteritis (127). Regardless of
treatment, however, the vision prognosis
of central RAO is poor (128).
4. Corneal diseases
Patients with diabetes are known to ex-
hibit abnormalities of the corneal epithe-
lium, leading to corneal erosion,
persistent epithelial defect, or corneal ul-
cers. Recurrent corneal erosions in pa-
tients with diabetes are usually
posttraumaticandtheresultofapparently
mild epithelial breakdown following cat-
aract or vitreoretinal surgery (129–131).
A reduction in hemidesmosomes may
contribute to a weakness in the adhesion
of diabetic corneal epithelium to the un-
derlying stroma (132). In addition, eryth-
rocyte aldose reductase increase has been
reported in patients with type 2 diabetes,
leading to high accumulation of sorbitol,
whichcandamagethecornealepithelium
(133). In one study, corneal abnormali-
ties (gerontoxon, limbal vascularization,
punctatekeratopathy,endothelialdystro-
phy, recurrent erosion, and ulcers) were
detected in up to 73.6% patients with di-
abetes (134). Patients with corneal dis-
ease often present with pain,
photophobia, blurred vision, and hyper-
emia. However, patients with diabetes of-
ten have reduced corneal sensitivity as
part of diabetes complication in periph-
eral nerves and limbal vasculopathy
(135).
Patients with diabetes who wear con-
tact lenses must take extra hygiene care
and be warned to seek advice early if any
irritation symptom develops to prevent
visionlossfrommicrobialkeratitis.Treat-
ment of corneal disease includes topical
antibiotics and topical cycloplegic (short
term), and corneal patching for 24 h is
indicated if the original insult is of nonor-
ganic nature (not from plant or soil
sources), for large corneal lesions (2
cm), and in non–contact lens users. Con-
tact lens–related conditions including
corneal ulcers and large abrasions need
urgentreferraltotheophthalmologist.All
other corneal cases need to be reviewed
the next day by the primary care
physician.
CONDITIONS
MASQUERADING AS
DIABETIC RETINOPATHY
There are a range of common ocular and
systemic conditions that can mimic dia-
beticretinopathyinpatientswithdiabetes
(136).
1. Age-related macular degeneration
Although many population-based studies
have shown that people with diabetes are
not at higher risk of age-related macular
degeneration(AMD)(137–143),thereare
similarities between AMD and diabetic
retinopathy. First, retinal signs (e.g.,
hemorrhages and hard exudates) of neo-
vascular or “wet” AMD are sometimes
confused with diabetic macular edema,
particularlyamongolderpatientswithdi-
abetes. Second, the key pathogenic pro-
cessinneovascularAMDandproliferative
retinopathy is an increased expression of
VEGFs. Chronic inﬂammation is also a
possible common pathophysiologic
mechanismofbothconditions(144,145).
Advanced glycation end products, for ex-
ample, have been found in drusen, a typ-
ical lesion of early-stage AMD (146).
Third, there is now good evidence that
anti-VEGF treatment is effective for both
neovascular AMD and proliferative reti-
nopathy (147–149).
2. Hypertensive retinopathy
Signs of hypertensive retinopathy are fre-
quentlyseeninadultsover40yearsofage
and may include arteriosclerotic changes
(arteriolar narrowing, arterio-venous
crossing changes, or arterio-venous nick-
ing), arteriolar wall changes (copper/
silver wiring), cotton wool spots,
hemorrhages, or edema. Many patients
with diabetes have hypertension, and
some of the more severe signs of hyper-
tensive retinopathy are similar to diabetic
retinopathy. Like diabetic retinopathy,
the presence of hypertensive retinopathy
signals widespread microvacular damage
and predicts subsequent events of stroke,
congestive heart failure, and cardiovascu-
larmortality,independentlyoftraditional
risk factors (150–153). Early recognition
of the ocular effects of blood pressure
could allow physicians to better manage
patients with hypertension and to moni-
tor its end-organ effects (154).
3. Radiation retinopathy
Radiation retinopathy presents progres-
sively degenerative and proliferative vas-
cular changes, primarily affecting the
macula, ranging from microaneurysm to
telangiectasia, intraretinal hemorrhages,
and neovascularization (155). Radiation
retinopathy can have a delayed onset
months to years after radiation treatment,
and patients with diabetes and hyperten-
sion are more susceptible to radiation ret-
inopathy (156) due to intensifying
oxygen-derivedfree-radicalassaultonthe
vascular cells (155). Patients with mini-
mal diabetic retinopathy undergoing che-
motherapy may suffer vision loss from
radiation retinopathy resulting from low-
doseradiationthatisconsideredtobesafe
andproperlyfractionated(157).Sincera-
diation retinopathy and diabetic retinop-
athy are identical clinically and
histopathologically, treatment for this
condition has been based on established
therapy for diabetic retinopathy such as
laser photocoagulation (158).
4. Other causes of retinopathy
Typical diabetic retinopathy lesions such
as cotton wool spots, retinal microaneu-
rysms, and retinal hemorrhage are also
seen in eyes with branch RVO. Other sys-
temicconditionsthatmayresultinsimilar
signs include HIV/AIDS (159), various
connective tissue diseases (Bechet’s dis-
ease, temporal arteritis, systemic lupus
vasculitis, sarcoidosis, sickle cell retinop-
athy, and Wegener’s granulomatosis),
andretinaltelangiectasias(Leber’smiliary
aneurysm, Coats’ disease, and idiopathic
juxtafoveal telangiectasia), a group of
rare, idiopathic, congenital retinal vas-
cular anomalies affecting the retinal
capillaries.
CONCLUSIONS — A wide spectrum
of ocular conditions other than diabetic
retinopathy is associated with diabetes.
Some of these conditions appear to be
causally linked to hyperglycemia and di-
abetes (e.g., cataract), whereas diabetes
may be only one of many risk factors for
other conditions (e.g., RVO and retinal
arteriolar emboli). In addition, there are a
range of retinal conditions (e.g., hyper-
tensive and radiation retinopathy) that
mimic common diabetic retinopathy
signs.
The management of diabetes-related
eyediseasesisprimarilypreventative,and
regular eye examinations and appropriate
ophthalmology referral remains the key
strategy to reduce the impact of diabetes-
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sion loss associated with most of the
conditions discussed is gradual. Occa-
sionally, however, more urgent referral to
an ophthalmologist is needed, as acute
surgical or laser intervention can save a
patient’s vision. While clinical trials have
demonstrated that good glycemic control
reduces the incidence and progression of
diabetic retinopathy (3), it is unclear
whether the same beneﬁcial effect applies
to other diabetes-related ocular condi-
tions (160). It is also unclear whether
controlling for relevant risk factors (e.g.,
blood pressure and lipids) can alter the
course of these ocular conditions.
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